Matches in Nanopublications for { ?s ?p "[EBV(+) MTX-associated B-LPD differed from PCLBCL-LT by the presence ulcerative skin lesions, marked tumor cell polymorphism, reduced staining for CD79a, and expression of CD30 and EBV.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- assertion description "[EBV(+) MTX-associated B-LPD differed from PCLBCL-LT by the presence ulcerative skin lesions, marked tumor cell polymorphism, reduced staining for CD79a, and expression of CD30 and EBV.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[EBV(+) MTX-associated B-LPD differed from PCLBCL-LT by the presence ulcerative skin lesions, marked tumor cell polymorphism, reduced staining for CD79a, and expression of CD30 and EBV.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[EBV(+) MTX-associated B-LPD differed from PCLBCL-LT by the presence ulcerative skin lesions, marked tumor cell polymorphism, reduced staining for CD79a, and expression of CD30 and EBV.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[EBV(+) MTX-associated B-LPD differed from PCLBCL-LT by the presence ulcerative skin lesions, marked tumor cell polymorphism, reduced staining for CD79a, and expression of CD30 and EBV.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[EBV(+) MTX-associated B-LPD differed from PCLBCL-LT by the presence ulcerative skin lesions, marked tumor cell polymorphism, reduced staining for CD79a, and expression of CD30 and EBV.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[EBV(+) MTX-associated B-LPD differed from PCLBCL-LT by the presence ulcerative skin lesions, marked tumor cell polymorphism, reduced staining for CD79a, and expression of CD30 and EBV.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1180283.RAnFxsXA7wmvVABj41_ZE7Reo8AonYs4YfG1bIFSkNrLg130_assertion description "[EBV(+) MTX-associated B-LPD differed from PCLBCL-LT by the presence ulcerative skin lesions, marked tumor cell polymorphism, reduced staining for CD79a, and expression of CD30 and EBV.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1180283.RAnFxsXA7wmvVABj41_ZE7Reo8AonYs4YfG1bIFSkNrLg130_provenance.
- NP940743.RAnTIdJUiuNIK_PBEi0bsec8LH91wGDGv4whSb90lpXLY130_assertion description "[EBV(+) MTX-associated B-LPD differed from PCLBCL-LT by the presence ulcerative skin lesions, marked tumor cell polymorphism, reduced staining for CD79a, and expression of CD30 and EBV.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP940743.RAnTIdJUiuNIK_PBEi0bsec8LH91wGDGv4whSb90lpXLY130_provenance.
- NP292421.RAJCQFNQtNOS7R3cgiyao0eSlwWqD_yWeB_SBEM5U-8o8130_assertion description "[EBV(+) MTX-associated B-LPD differed from PCLBCL-LT by the presence ulcerative skin lesions, marked tumor cell polymorphism, reduced staining for CD79a, and expression of CD30 and EBV.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP292421.RAJCQFNQtNOS7R3cgiyao0eSlwWqD_yWeB_SBEM5U-8o8130_provenance.
- NP1180284.RAOx-LD-vn4MoLYTM0oQ5z726x07tXMCG2dTcrWT54V3A130_assertion description "[EBV(+) MTX-associated B-LPD differed from PCLBCL-LT by the presence ulcerative skin lesions, marked tumor cell polymorphism, reduced staining for CD79a, and expression of CD30 and EBV.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1180284.RAOx-LD-vn4MoLYTM0oQ5z726x07tXMCG2dTcrWT54V3A130_provenance.
- NP869849.RA57WN73TRLcKCKwFAbFVk-GrMz19NaZ6IX8WRDKly_4c130_assertion description "[EBV(+) MTX-associated B-LPD differed from PCLBCL-LT by the presence ulcerative skin lesions, marked tumor cell polymorphism, reduced staining for CD79a, and expression of CD30 and EBV.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP869849.RA57WN73TRLcKCKwFAbFVk-GrMz19NaZ6IX8WRDKly_4c130_provenance.
- NP1180285.RA3ZaTK9ragYqWXRXQDH4DcfFFmcYyJxhNE-Xme3hAF-0130_assertion description "[EBV(+) MTX-associated B-LPD differed from PCLBCL-LT by the presence ulcerative skin lesions, marked tumor cell polymorphism, reduced staining for CD79a, and expression of CD30 and EBV.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1180285.RA3ZaTK9ragYqWXRXQDH4DcfFFmcYyJxhNE-Xme3hAF-0130_provenance.